Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Scott Gottlieb Doctors in Belgium have discovered that a Chinese herb,
Aristolochia fangchi, already linked to kidney failure, may cause cancer as well.
Patients at a Belgian weight loss clinic were given this herb in error.
Staff at the clinic had prescribed the herb Stephania tetrandra, but
the pills that patients received also included aristolochia, possibly
because of a manufacturing error. On average, the patients took the two
herbs for about a year.
Of the patients who accidentally received the herb, 18 developed
cancers of the urinary system, according to the report. These 18 patients had already experienced severe kidney failure as a result of
taking another combination of two Chinese herbs (S tetrandra and
Magnolia officinalis) and needed kidney dialysis or kidney transplants
(New England Journal of Medicine 2000;342:1686-92).
The Chinese name for A fangchis is similar to that for S tetrandra, and
it is often substituted for stephania. "Since there is virtually no
control over the quality of these products, it is not unusual not to
know what is actually in herbal preparations and dietary
supplements," wrote Dr David Kessler, the former commissioner of the
US Food and Drug Administration, in an accompanying editorial.
Dr Joelle Nortier from Université Libre de Bruxelles in Brussels,
Belgium, and associates first became aware of the extent of the cancer
risk after discovering a urinary system cancer in one of their patients
undergoing transplantation.
The researchers then offered preventive removal of the kidneys and
ureters to 43 other patients being treated for kidney disease that was
related to treatment with Chinese herbs. Thirty nine patients accepted
the offer, and that is when the 18 cancers were discovered,
representing a cancer rate of 46
In 19 of the 21 patients without cancer, mild to moderate precancerous
abnormalities were found in the ureters or kidneys, according to the report.
All the affected kidneys showed evidence of exposure to aristolochic
acid, the harmful ingredient in A fangchi, and lower levels were found
in some of the ureters. Only four samples contained evidence of
exposure to ochratoxin A, a possible carcinogen sometimes found in S tetrandra.
The risk of cancer was greater for patients who had taken larger
amounts of A fangchi, the investigators note. Eight of 24 patients who
took 200 g or less had urinary system cancer, compared with 10 of 15 patients who took 201 grams or more.
"Our findings reinforce the idea that the use of natural herbal
medicine may not be without risk," said Dr Nortier.
Cases of kidney failure from aristolochia have been reported in France,
Britain, Spain, Japan, Taiwan, and the United States. Last month, the
US Food and Drug Administration sent warning letters about the herb to
doctors and to the supplement industry.
Read all Rapid Responses
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.